Live feed07:00:00·26dPRReleasevia QuantisnowTonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.ByQuantisnow·Wall Street's wire, on your screen.TNXP· Tonix Pharmaceuticals Holding Corp.Health Care
